India's Venus Remedies jumps on FDA approval for anti-mircrobial resistance therapy

Venus Remedies

17/04/2025 06:44

** Shares of Venus Remedies VENR.NS jump 9.2% to 341.50 rupees, set for second-best day this year

** Drugmaker gets U.S. FDA nod to use its anti-microbial resistance therapy, VRP-034

** VRP-034 used for treating injury to kidney caused by polymyxin-based therapies

** Over 197,000 shares traded, 4.2x the 30-day avg volume

** Stock has risen 7.3% so far this year

(Reporting by Nandan Mandayam in Bengaluru)

((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))